WANBURY · NSE
Wanbury Limited
₹222.75
-0.40% (-₹0.9)
Prev. close
₹223.65
Volume
1,13,160
Delivery %
39.4%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid , Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was founded in 1988 and is headquartered in Navi Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Pradeep Patni
Headquarters
Navi Mumbai
Employees
1,200
Website
wanbury.comExchange
View on NSE ↗Key stats
Market cap
₹778.89 Cr
P/E ratio (TTM)
13.7
EPS (TTM)
₹16.30
Beta (1Y · daily vs NIFTY 50)
1.28
Beta (5Y · monthly vs NIFTY 50)
1.51
Shares float
1.82 Cr
EPS · quarter ended Jun 2026
₹0.92
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹392.52 Cr | ₹511.19 Cr | ₹499.65 Cr | ₹575.65 Cr | ₹599.51 Cr | ₹643.91 Cr | |
| EBITDA | ₹20.42 Cr | ₹113.19 Cr | ₹23.49 Cr | ₹98.55 Cr | ₹79.81 Cr | ₹104.09 Cr |
| ₹-12.61 Cr | ₹81.47 Cr | ₹-10.40 Cr | ₹55.96 Cr | ₹30.53 Cr | ₹66.13 Cr | |
| Diluted EPS | ₹-5.04 | ₹26.79 | ₹-3.18 | ₹16.89 | ₹8.98 | — |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
EBITDA for Mar 2022 could not be independently verified against the company's own annual report: this page shows ₹113.19 Cr while the annual report gives ₹36.82 Cr (67.5% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹24.59 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹287.60 Cr | ₹352.55 Cr | ₹303.87 Cr | ₹343.49 Cr | ₹413.92 Cr | ₹517.67 Cr | |
| — | — | ₹108.58 Cr | ₹115.80 Cr | ₹176.91 Cr | ₹224.37 Cr | |
| Stockholders' equity | — | — | ₹-32.82 Cr | ₹27.94 Cr | ₹59.27 Cr | ₹144.45 Cr |
Current assets, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹16.68 Cr | ₹37.56 Cr | ₹19.80 Cr | ₹4.70 Cr | ₹26.10 Cr | ₹31.53 Cr | |
| Investing cash flow | ₹8.04 Cr | ₹58.65 L | ₹-8.84 Cr | ₹-16.63 Cr | ₹-51.17 Cr | ₹-56.40 Cr |
| ₹-17.39 Cr | ₹-25.62 Cr | ₹-31.99 Cr | ₹14.55 Cr | ₹25.73 Cr | ₹22.42 Cr | |
| Capital expenditure | ₹0 | ₹0 | ₹-12.63 Cr | ₹-17.42 Cr | ₹-49.03 Cr | ₹-59.61 Cr |
| End cash position | ₹9.96 Cr | ₹22.53 Cr | ₹1.49 Cr | ₹3.40 Cr | ₹4.06 Cr | ₹1.61 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Jun 22 | Sep 22 | Dec 22–Jun 23(3Q) | Sep 23 | Dec 23–Jun 24(3Q) | Sep 24 | Dec 24–Mar 25(2Q) | Jun 25 | Sep 25–Sep 25(2Q) | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 39.90% | 39.89% | 39.85% | 39.85% | 39.84% | 39.80% | 39.79% | 39.77% | 39.76% | 39.63% | 43.09% | 43.07% | 43.02% |
| Public | 60.10% | 60.11% | 60.14% | 60.15% | 60.16% | 60.20% | 60.21% | 60.23% | 60.24% | 60.37% | 56.91% | 56.93% | 56.98% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Wanbury Limited | ₹778.89 Cr | ₹222.75 | 13.7 | 5.39 | 45.8% | 1.55 | +8.5% | -13.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 23
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Wanbury standalone net profit declines 75.98% in the June 2026 quarter
Business Standard · 1 month ago